Education
About Us
Working with TipRanks
Follow Us
Panbela Therapeutics (PBLA)
OTHER OTC:PBLA
PBLA Stock Chart & Stats
$0.01
<$0.01(1.80%)
At close: 4:00 PM EST
$0.01
<$0.01(1.80%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.47
Previous CloseN/A
Volume4.43K
Average Volume (3M)4.36K
Market Cap
$53.89K
Enterprise Value$2.67M
Total Cash (Recent Filing)$142.00K
Total Debt (Recent Filing)$6.39M
Price to Earnings (P/E)―
Beta-4.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,854,831
10 Day Avg. Volume549
30 Day Avg. Volume4,356
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-12.14
Price to Sales (P/S)0.00
P/FCF Ratio-2.27
Enterprise Value/Market Cap49.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.09
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Panbela Therapeutics News
PBLA FAQ
What was Panbela Therapeutics’s price range in the past 12 months?
Panbela Therapeutics lowest stock price was <$0.01 and its highest was $0.47 in the past 12 months.
What is Panbela Therapeutics’s market cap?
Panbela Therapeutics’s market cap is $53.89K.
When is Panbela Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Panbela Therapeutics’s earnings last quarter?
Currently, no data Available
Is Panbela Therapeutics overvalued?
According to Wall Street analysts Panbela Therapeutics’s price is currently Overvalued.
Does Panbela Therapeutics pay dividends?
Panbela Therapeutics does not currently pay dividends.
What is Panbela Therapeutics’s EPS estimate?
Panbela Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panbela Therapeutics have?
Panbela Therapeutics has 4,854,831 shares outstanding.
What happened to Panbela Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Panbela Therapeutics?
Currently, no hedge funds are holding shares in PBLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Panbela Therapeutics
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.